Zura Bio (ZURA) EBITDA (2022 - 2026)

Zura Bio's EBITDA history runs 5 years deep, the most recent figure standing at -$25.5 million for Q1 2026.

• On a quarterly basis, EBITDA fell 32.43% year-over-year to -$25.5 million in Q1 2026; TTM through Mar 2026 was -$81.5 million, a 23.35% decrease from a year earlier, with the FY2025 full-year figure at -$75.2 million, down 36.34% from the prior year.
• EBITDA retreated to -$25.5 million in Q1 2026 per ZURA's latest filing, from -$18.4 million in the prior quarter.
• Across five years, EBITDA topped out at -$927000.0 in Q2 2022 and bottomed at -$33.9 million in Q2 2023.
• The 5-year median for EBITDA is -$15.7 million (2024), against an average of -$14.5 million.
• Across the five-year window, EBITDA sank 3557.5% in 2023 and soared 65.32% in 2024, its largest moves.
• Year by year, EBITDA stood at -$17.3 million in 2022, then jumped by 37.59% to -$10.8 million in 2023, then plunged by 45.3% to -$15.7 million in 2024, then fell by 17.03% to -$18.4 million in 2025, then tumbled by 38.5% to -$25.5 million in 2026.
• Per Business Quant, the three latest ZURA EBITDA figures stand at -$25.5 million (Q1 2026), -$18.4 million (Q4 2025), and -$19.5 million (Q3 2025).